J&J abandons development of RSV compound from Alios deal

J&J revealed it has ceased development of lumicitabine (AL-8176), an antiviral compound that was a key to its $1.75 billion takeout of Alios in 2014. In a statement to BioCentury, the pharma said it has now discontinued all of the assets acquired via the Alios BioPharma Inc. deal.

In a regulatory filing late Thursday, Johnson & Johnson (NYSE:JNJ) said it will take an after-tax impairment charge of about $700 million this quarter based on lumicitabine's remaining value. J&J took a $630 million charge in 3Q18 after closing three trials of the candidate (see "J&J Stalls Development of Antiviral from Alios Deal")...